Chronic Administration of Anacetrapib Is Associated With Accumulation in Adipose and Slow Elimination

Clinical Pharmacology and Therapeutics

Volumn 102, Issue 5, 2017, Pages 832-840

  Krishna, R ^a   Gheyas, F ^a   Liu, Y ^a   Hagen, D R ^a   Walker, B ^a   Chawla, A ^a   Cote, J ^a   Blaustein, R O ^a   Gutstein, D E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; CETP PROTEIN, HUMAN; CHOLESTEROL ESTER TRANSFER PROTEIN; HYPOCHOLESTEROLEMIC AGENT; OXAZOLIDINONE DERIVATIVE;

ADIPOSE TISSUE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG PROTEIN BINDING; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIPID DIET; LIPOPHILICITY; LOW FAT DIET; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG ADMINISTRATION; DRUG EFFECTS; METABOLISM; MIDDLE AGED;

ADIPOSE TISSUE; ADULT; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL ESTER TRANSFER PROTEINS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES;

EID: 85018311954     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.700     Document Type: Article

References (20)

1. Hartmann, G. et al. Disposition into adipose tissue determines accumulation and elimination kinetics of the cholesteryl ester transfer protein inhibitor anacetrapib in mice. Drug Metab. Dispos. 44, 428–434 (2016).
2. Gutstein, D.E. et al. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction. Clin. Pharmacol. Ther. 91, 109–122 (2012).
3. Cannon, C.P. et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med. 363, 2406–2415 (2010).
4. Gotto, A.M. Jr et al. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am. J. Cardiol. 113, 76–83 (2014).
5. Wasan, K.M., Brocks, D.R., Lee, S.D., Sachs-Barrable, K. & Thornton, S.J. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat. Rev. Drug Discov. 7, 84–99 (2008).
6. Ranalletta, M. et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J. Lipid Res. 51, 2739–2752 (2010).
7. Krishna, R. et al. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. 68, 535–545 (2009).
8. Krishna, R. et al. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin. Pharmacol. Ther. 84, 679–683 (2008).
9. Dansky, H.M. et al. Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia. Am. Heart J. 162, 708–716 (2011).
10. Smith, C.J. et al. Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib. J. Med. Chem. 54, 4880–4895 (2011).
11. Lafuente-Lafuente, C. et al. Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity. Br. J. Clin. Pharmacol. 67, 511–519 (2009).
12. Cypess, A.M. et al. Identification and importance of brown adipose tissue in adult humans. N. Engl. J. Med. 360, 1509–1517 (2009).
13. Saely, C.H., Geiger, K. & Drexel, H. Brown versus white adipose tissue: a mini-review. Gerontology 58, 15–23 (2012).
14. Barton, P., Davis, A.M., McCarthy, D.J. & Webborn, P.J. Drug-phospholipid interactions. 2. Predicting the sites of drug distribution using n-octanol/water and membrane/water distribution coefficients. J. Pharm. Sci. 86, 1034–1039 (1997).
15. Weiss, M. The anomalous pharmacokinetics of amiodarone explained by nonexponential tissue trapping. J. Pharmacokinet. Biopharm. 27, 383–396 (1999).
16. Quinet, E.M., Heurta, P., Nancoo, D., Tall, A.R., Marcel, Y.L. & McPherson, R. Adipose tissue cholesteryl ester transfer protein mRNA in response to probucol treatment: cholesterol and species dependence. J. Lipid Res. 34, 845–852 (1993).
17. Perlman, M.E. et al. Development of a self-emulsifying formulation that reduces the food effect for torcetrapib. Int. J. Pharm. 351, 15–22 (2008).
18. Wasan, K.M. & Cassidy, S.M. Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J. Pharm. Sci. 87, 411–424 (1998).
19. Cannon, C.P. et al. Design of the DEFINE trial: determining the efficacy and tolerability of CETP inhibition with anacetrapib. Am. Heart J. 158, 513–519 (2009).
20. Eveland, S.S. et al. A high-precision fluorogenic cholesteryl ester transfer protein assay compatible with animal serum and 3456-well assay technology. Anal. Biochem. 368, 239–249 (2007).